Compare Innodata Inc (INOD) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innodata Inc vs TransMedics Group Inc — how do they compare? Innodata Inc trades at $64 (market cap $2.03B), while TransMedics Group Inc trades at $74.7 (market cap $2.54B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and Innodata Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| INOD | TMDX | |
|---|---|---|
Market Cap | $2.03B | $2.54B |
Sector | Technology | Technology |
52-Week High | $121.50 | $150.42 |
52-Week Low | $34.45 | $61.99 |
Enterprise Value | $1.91B | $2.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INOD trades at $62.08, up 2.09% today, showing strong momentum despite a bearish technical signal. The company demonstrates robust fundamentals with revenue growth from $252M in 2025 to $283M projected for 2026, and net income margins improving to 13.86%. Recent earnings beats and positive AI-driven news highlight growing demand for its engineering R&D services. Technical indicators show mixed signals with RSI suggesting oversold conditions but moving averages indicating bearish pressure.
Outlook remains positive with 60% analyst buy ratings and a $130 consensus price target representing 109% upside. Key opportunities include AI market expansion and customer diversification, while risks center on high valuation multiples (P/E 54.29) and customer concentration. The stock's recent 33% pullback may present a buying opportunity for growth-oriented investors.
TransMedics (TMDX) trades at $73.47, down 0.69% with neutral technical signals. The stock shows strong profitability with 27% net margins and 45% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in European aviation logistics aims to expand the Organ Care System platform. Analyst consensus remains bullish with a $108.71 price target representing 48% upside potential.
Long-term growth prospects appear solid given TMDX's expanding transplant ecosystem, but near-term margin pressure from expansion investments and execution risks warrant caution. The company maintains competitive advantages in organ transplant logistics, though increased spending and competitive threats from alternatives like Strata Critical Medical present headwinds for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
